Compare Organon & Co. Common Stock (OGN) vs VICI Properties Inc (VICI) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

VICI Properties trades at $22.91, down 0.52% on the day, with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and 9.84% ROE. The stock shows mixed earnings performance with one beat and two misses in recent quarters, while analyst consensus remains strongly bullish with a $28.90 price target representing 26% upside. Recent corporate actions include a $0.46 dividend payment scheduled for October 2026.

The investment case balances attractive valuation metrics (P/E of 8.88, P/B of 0.86) against technical weakness and tenant concentration risks. While cash flow generation remains robust with $2.51B from operations in 2025, investors face headwinds from rising interest rates and potential tenant stress. The 75% buy rating from analysts suggests significant upside potential if execution remains strong.